click enter text
full postview slight miss ep
report financi result tuesday morn revenu
in-lin consensu miss slightli ep mainli due
higher sg expens gave revenu ep
guidanc slightli us consensu although hard
know real consensu moment come heel
manag recent exud confid long-term outlook recent
also announc slight slippag timelin ibranc adjuv
palla trial read-out late earli addit
announc repurchas share activ
busi develop asset otherwis invest
estim declin slightli pt rise base
valu sotp basi ahead split upjohn busi
price target repres new ex-upjohn ep
estim plu ownership stake viatri name new
myl upjohn entiti form guidanc mid-year
bodi report full analysi
inform stock cover see recent report
 januari issu monthli controversi
trade fundament data
upsid target
factset/wolf research price jan
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday open
report result in-lin consensu revenu miss slightli ep
gave first-tim revenu ep guidanc slightli us seemingli consensu
saw share price declin
overal impress report financi result in-lin revenu miss ep
cent also provid detail guidanc give addit financi detail relat pend
split upjohn busi new ex-upjohn revenu ep
guidanc fall short slightli us/consensu even adjust new disclosur
addit part busi may go final yet recent broker confer san
francisco manag wide view exud high degre confid futur outlook
backdrop miss ep give temper guidanc seem contradict
like explain share around confer call variou addit updat
provid varieti front major aha moment ask whether recent
surpris approv domest prevnar-look alik china could game changer either china
market walvax biotech may potenti seek launch say brief assess
risk see link also ask whether plan may put hold first half
year pend upjohn separ say suggest deal done presum
one reason share buyback bright spot continu newli launch vyndaqel
tafamidi us product ramp nice may bolu effect cogniz
think ramp subsequ quarter notwithstand new excit product
compani term outlook compani continu paint bullish pictur
talk best-in-class long-term revenu growth right price-to-earnings multipl would attract
math suggest ex-upjohn basi adjust price-to-earnings multipl alreadi account
degre uncertainti compani two biggest franchis prevnar ibranc becom
clearer cours year downsid could exceed upsid given investor expect
current rate peer perform
addit detail us/eu drug compani cover see januari
issu monthli controversi report
quarterli perform term sale ep exhibit
revenu report sale vs consensu
ep report non-gaap ep vs consensu
ibranc sale vs consensu
prevnar sale vs consensu
vyndaqel sale vs consensu
page
revenu given w/uj w/o uj slightli
ep given w/uj w/o uj also w/o uj
pipelin one materi disclosur read-out one ibranc adjuv trial palla slip late
slippag oncolog trial usual good sign alway case
slippag seem minim remind hold investor day focu pipelin march
revenu decreas ep decreas
revenu estim decreas ep estim decreas
depend year
ep compound-annual-growth-rate increas slightli vs prior peer averag ep
compound-annual-growth-rate
price target increas use sotp analysi ahead spin-off upjohn
sharehold stake sotp repres price-to-earnings multipl updat
ep estim w/o uj plu viatri pt impli price-to-earnings ep
new w/o uj ignor viatri stake
new i/e ex-upjohn total revenu cc share repurchas instead invest
busi revenu guidanc impli sale growth midpoint
upjohn total revenu cc china cc due vbp lipitor norvasc upjohn
guidanc chang element given previous
 si higher expect increas invest variou brand
 repurchas share differ compani best class grower
continu need invest busi includ capital-expenditure anoth reason buyback dividend
page
 transfer upjohn chang anyth noth decid yet still work
term
 revenu compound-annual-growth-rate still hold say absolut also remind risk-adjust
pipelin hit revenue growth could doubl digit pipelin fail would low
 sort target consid say never say never come deal
realli look larg gener look smaller deal
 confirm spin split upjohn dividend treat ye
spin split net basi reduct dividend sum togeth across biopharma
stake upjohn myl investor receiv
 pfe plan hold ahead separ hold expect sever
transact
file new formul adult y/e follow dose data wolf comment prior
assess risk mrk product may pose see link
 view product vs mrk say offer provid better
adult coverag infant us ex-u coverag differenti even higher adult
data share like confer
 talk recent surpris approv chines prevnar look-alik product
could happen china market outsid china domest compani decid
launch region acknowledg ye new competitor note
differ differ older conjug technolog said competitor
new birth china everi year get vaccin think plenti room multipl
product grow product offer qualiti reliabl expect remain pocket
cost patient address could happen market outsid china
palla read earli vs late previous
 palla slip time describ slippag week later due lower event
say draw conclus interim analysi yet point expect trial
 ibranc row trend headwind continu see good growth ex-u temper sale growth
price eros gain access note share within class
diagnosi rate prior launch
page
 sequenti sale growth high script growth would suggest differ
patient mix impact gross-to-net diagnosi rate continu increas dynam
 bolu effect linear growth go forward ye say may bolu effect
confid right set tool help drive diagnos
 larg untap patient popul reach claim patient
us global date diagnos us popul say long way go find
 europ given drug alreadi approv new cardiomyopathi indic price eu
go higher ramp like look like remind lag approv
price negoti on-going polyneuropathi approv eu cardiomyopathi total differ
indic address like rate uptak indic clearli whether price could go higher
 given data cm pull-through polyneuropathi indic us still explor
possibl
 sale indic impact rinvoq see good growth across indic
excit rinvoq market spur class growth
 data hand yet top-lin still confid superior itch relief vs dupxent still
expect head claim yet seen data still expect itch relief
 commerci expect us roll-out biosimilar believ oncolog differ vs inflectra
biosimilar remicad struggl gain share believ uptak much quicker
patient cycl quickli vs remicad us competitor oncolog
biosimilar presum refer avastin biosimilar show good share gain
portfolio biosimilar launch close proxim relationship provid price
 updat gave quick noth new say answer
 tanezumab updat complet submiss pursu eu ja includ
low dose await accept file see signific potenti oa
 dmd updat protocol amend recent recal prior report function
trend improv conclud spring start later year
page
 dmd data present commit venu suggest
 gene therapi broadli lay ahead expect bring one new therapi clinic year
forese futur
 hemophilia determin get chronic drug therapi vs gene therapi younger
patient would one group better suit gene therapi variou reason
exhibit show compani report actual result vs estim consensu
exhibit pfizer result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit pfizer guidanc vs wr estim old new
page
oldnewoldnewrevenu brevenu w/o ujapprox bgross br bother incom /expenseapprox meffect tax rateapprox dilut dilut ep w/o uj guidanc incl uj wolf research estim
exhibit captur chang forecast
exhibit chang wr model upjohn exclud
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom relat in-process epsshar outstand total profit profit incom
page
product revenu immunolog total
exhibit wr balanc sheet cash flow statement
page
flow statement earn in-process sale impair restructur defer compens asset flow oper activ sale sale busi net invest flow invest activ chang short term repay long-term common dividend flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock cent par valu paid-in comprehens treasuri stock sharehold liabil sharehold
